The bispecific antibody—which targets the IL-23p19 and TL1A pathways—was licensed from China’s Qyuns Therapeutics. Since ...

Throughout 2025, AbbVie’s Skyrizi and Johnson & Johnson’s Tremfya were mainstays at the top of the monthly TV drug ad spending rankings. Indeed, since September, they’d taken turns alternating between ...

A test that rapidly detects signs of inflammatory bowel disease (IBD) in stool samples could improve future diagnosis and ...

Tremfya and Icotide are touted as key growth drivers in J&J’s strongly performing innovative medicines business.

Xoma argued Janssen breached the contract Xoma had with the third-party pharmaceutical company, as well as the contract the company and Janssen had, by failing to obtain a commercial license from Xoma ...

The Crohn's & Colitis Foundation today revealed compelling new research pointing to major healthcare access challenges and financial burdens disproportionately affecting young adults with Inflammatory ...

AbbVie Inc. (NYSE:ABBV) is one of the best stocks for the next decade. On December 12, Morgan Stanley raised the firm’s price target on AbbVie to $269 from $261 with an Overweight rating on the shares ...

Advanced therapies improved bowel urgency in 50.9% of patients with inflammatory bowel disease (IBD), with a reduction in the severity of urgency. These improvements correlated with clinical, ...